This CPB is revised to state that bendamustine (Bendeka, Treanda) is considered medically necessary for the following indications: 1) nodal marginal zone lymphoma, in combination with rituximab or obinutuzumab; 2) second-line or subsequent therapy for relapsed or refractory monomorphic epitheliotropic intestinal T-cell lymphoma; 3) HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, as second-line or subsequent therapy with or without rituximab  for relapsed or refractory disease in noncandidates for high-dose therapy. This CPB is revised to state that bendamustine for the following indications is considered medically necessary when criteria are met: 1) adult T-cell leukemia/lymphoma - second-line therapy as a single agent; 2) AIDS-related B-cell lymphoma (AIDS-related diffuse large B-cell lymphoma, and primary effusion lymphoma - second-line or subsequent therapy with or without rituximab for relapsed or refractory disease in non-candidates for high-dose therapy; 3) chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) -  first-line therapy with or without rituximab, ofatumumab, or obinutuzumab for CLL/SLL without del(17p)/TP53 mutation. or therapy for relapsed or refractory disease without del(17p)/TP53 mutation in combination with rituximab and with or without ibrutinib or idelalisib; 4) classical Hodgkin's lymphoma - use as a single agent for relapsed or refractory disease ior palliative therapy in older adults (> 60); 5) diffuse large B-cell lymphoma - second-line or subsequent therapy with or without rituximab for relapsed or refractory primary cutaneous diffuse large B-cell lymphoma, leg type in noncandidates for high-dose therapy; 6) follicular lymphoma - as a single agent or in combination with rituximab or obinutuzumab; 7) gastric MALT lymphoma - in combination with rituximab or orbinutuzumab; 8) mantle cell lymphoma - as a single agent or in combination with rituximab with or without bortezomib; 9) multiple myeloma - therapy for previously treated myeloma for relapsed or progressive disease; 10) mycosis fungoides/Sezary syndrome - single agent therapy for tumors with aggressive growth rate; 11) non-gastric MALT lymphoma - in combination with rituximab or obinutuzumab; 12) peripheral T-cell lymphoma (relapsed or refractory angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified, anaplastic large cell lymphoma, or enteropathy-associated T-cell lymphoma) - second-line or subsequent therapy for relapsed or refractory disease; 13) primary cutaneous CD30+ T-cell lymphoproliferative disorders (primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions and cutaneous ALCL with regional nodes (excludes systemic ALCL)) - single-agent therapy for relapsed or refractory disease; 14) primary cutaneous B-cell lymphoma (primary cutaneous marginal zone or follicle center lymphoma)  - used in combination with rituximab or obinutuzumab; 15) small cell lung cancer - subsequent chemotherapy as a single agent for relapsed or progressive disease; 16) splenic marginal zone lymphoma - in combination with rituximab or obinutuzumab; 17) Waldenstrom's macroglobulinemia/Lymphoplasmacytic lymphoma - as a single agent or in combination with rituximab. This CPB has been revised to state that bendamustine is considered experimental and investigational for anaplastic glioma, blastic plasmacytoid dendritic cell leukemia, hepatic lymphoma, and primary central nervous system (CNS) lymphoma.